KNW KNOW LABS INC.

Know Labs Sensor Technology in Steering Wheels Could Curb Impaired Driving

Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive sensor technology, announced today that it has retained The Stanbridge Group to secure a strategic relationship with an automotive original equipment manufacturer to embed the Know Labs sensor technology in automobile steering wheels. In early preliminary tests, the Know Labs sensor demonstrated, in a laboratory setting, that it can non-invasively determine blood alcohol levels and the Company believes, in an automobile steering wheel, could prohibit an impaired individual from driving.

This discovery occurred during the early development of the Company’s non-invasive glucose monitoring technology. That lead to the filing in 2022 by Know Labs of a patent entitled, “” on August 15, 2022. It was published on February 15, 2024, with publication number: US 2024/0050007 A1.

Tucked within President Biden's 2021 Infrastructure Investment and Jobs Act is a mandate set to redefine the landscape of DUI prevention. By as early as 2026, all new vehicles sold within the country will need to be equipped with passive alcohol detection systems. The Know Labs platform directly addresses this issue.

“While inventing and developing the Know Labs non-invasive diagnostic technology we have paid close attention to the many diverse fields of use in which our technology could be applied,” said Ron Erickson, Know Labs’ CEO. “Determining driver health and wellness is one of those fields of use. Our broad patent portfolio covers installing our sensor technology in an automobile steering wheel. We believe our sensor technology, embedded in steering wheels, can keep drunk drivers off the road and become the standard for the global auto industry. The Stanbridge Group is working to secure a joint venture partner for this exciting application of our platform technology while we continue the Company’s core focus on non-invasive blood glucose monitoring.”

In 2022, drunk driving was responsible for 13,524 deaths in the United States according to the (“NHTSA”). As a consequence, NHTSA has initiated a proposed rule making process regarding .

The Stanbridge Group, led by founder, Rick Stanbridge, has worked with senior leadership of automobile and original equipment automobile equipment manufacturers for many years. “Automobile and component manufacturers are all looking for a way to prevent impaired drivers from operating their vehicles,” stated Rick Stanbridge. “The Know Labs sensor is a perfect solution for the problem manufacturers and the NHTSA are working to solve. We are thrilled to be working with Know Labs on this important project.”

For more information on Know Labs, visit .

About Know Labs, Inc.

is a public company whose shares trade on the NYSE American Exchange under the stock symbol “KNW.” The Company’s platform technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology is designed to able to integrate into a variety of wearable, mobile or bench-top form factors. The Company believes that this patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The Company’s first expected application of the technology will be in a product marketed as a non-invasive glucose monitor. The device is designed to provide the user with accessible and affordable real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration clearance prior to its introduction to the market.

About The Stanbridge Group

The Stanbridge Group conducts business in the United States and around the world. Their focus is on helping companies grow to the next level of expansion and profitability regardless of their geographic location. Most people forget that behind every large corporation there was once a small business. All the big corporate names here in the United States began as an entrepreneurial idea, with only a few employees, a market to fill, and the will and vision to grow. The Stanbridge Group has the tools and resources to take your business to the next level. For more information on The Stanbridge Group, visit

Safe Harbor Statement

This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2023, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.

EN
16/10/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on KNOW LABS INC.

 PRESS RELEASE

Know Labs, Inc. Announces $300K Registered Direct Offering

SEATTLE--(BUSINESS WIRE)-- (NYSE American: KNW) (the "Company"), a leading developer of non-invasive medical diagnostic technology, today announced the pricing of a registered direct offering with gross proceeds to the company of  $300K before deducting placement agent fees and other estimated expenses payable by the Company. This was a unit offering comprised of one share of stock and one warrant. The purchase price of the unit was $0.24 a share and the warrant is exercisable at $0.24. The warrants will expire on the fifth anniversary of the warrant issuance. The warrants also have a cashl...

 PRESS RELEASE

Know Labs, Inc. Announces NYSE American Acceptance of Plan to Regain C...

SEATTLE--(BUSINESS WIRE)-- (NYSE American: KNW), leading developer of non-invasive diagnostics technology, today announced that on December 10, 2024, it received notification (the "Acceptance Letter") from the NYSE American LLC (the "NYSE American") that the Company's previously-submitted plan to regain compliance with the NYSE American's listing standards (the "Plan") was accepted. In the Acceptance Letter, NYSE American granted the Company until March 27, 2026 (the "Plan Period"), to regain compliance with the continued listing standards. During the Plan Period, the Company will be subjec...

 PRESS RELEASE

Know Labs, Inc. Reports Fourth Quarter and Fiscal Year 2024 Results

SEATTLE--(BUSINESS WIRE)-- (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the fourth quarter and fiscal year ended September 30, 2024. Financial Highlights: Know Labs reported a net loss of $16.58 million dollars in FY2024, compared to a net loss of $15.29 million dollars in FY2023, an increase in net loss of 8.4%. This translates to Earnings Per Share of a loss of $0.20, better than FY2023 Earnings Per Share Loss of $0.41, an improvement of 51%, before preferred stock dividends. In FY2024, recorded a non...

 PRESS RELEASE

Know Labs Announces Expanded Technology Leadership in its Executive Te...

SEATTLE--(BUSINESS WIRE)-- Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive diagnostics technology, announced today two additions to its executive leadership team. The new executives are John Cronin and Dominic Klyve, Ph.D. They are tasked with both furthering the development of the Company’s non-invasive diagnostic technology platform and building relationships with potential strategic partners. “John and Dominic bring extensive technology leadership and research experience to the Know Labs team,” said Ron Erickson, CEO. “In their new roles they provide intellectual ...

 PRESS RELEASE

Know Labs Sensor Technology in Steering Wheels Could Curb Impaired Dri...

SEATTLE--(BUSINESS WIRE)-- Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive sensor technology, announced today that it has retained The Stanbridge Group to secure a strategic relationship with an automotive original equipment manufacturer to embed the Know Labs sensor technology in automobile steering wheels. In early preliminary tests, the Know Labs sensor demonstrated, in a laboratory setting, that it can non-invasively determine blood alcohol levels and the Company believes, in an automobile steering wheel, could prohibit an impaired individual from driving. This d...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch